Antibiotic Stewardship Basics for Junior Doctors: ECDC, WHO AWaRe and Everyday Practice

Most hospital antibiotics are not prescribed by infectious diseases specialists. Junior doctors write them in the emergency department, on the ward and overnight. That makes antimicrobial stewardship part of everyday work rather than a niche topic. This article covers the European context, the WHO AWaRe framework and the habits that make the most difference on a ward. It does not give drug or dosing recommendations; those belong in your local guideline.

Why it matters

According to the European Centre for Disease Prevention and Control (ECDC), more than 35,000 people die each year in the EU from infections caused by antibiotic-resistant bacteria [1]. On any given day about one in three hospital patients receives at least one antimicrobial, and ECDC notes that up to 50% of hospital antibiotic use can be inappropriate [2]. Bloodstream infections with carbapenem-resistant Klebsiella pneumoniae rose by almost 60% in the EU between 2019 and 2023 [2].

The framework: EU targets and WHO AWaRe

EU targets for 2030

In June 2023 the Council of the EU adopted targets for 2030, using 2019 as the baseline [1, 3]:

ECDC's November 2023 report put the EU-wide Access share at 59.8%, with only nine Member States at or above 65% [1].

What AWaRe means

The WHO groups antibiotics by their impact on antimicrobial resistance. The classification is updated every two years, most recently in 2023 [4]:

• Access: narrow spectrum, fewer side effects, lower resistance potential; first or second choice for common infections.
• Watch: broader spectrum and higher resistance potential; first choice only for a limited set of indications, and use should be closely monitored.
• Reserve: "last resort" antibiotics for highly selected patients, such as those with life-threatening infections caused by multidrug-resistant bacteria.

(These descriptions follow the UK-AWaRe version, which is based on the WHO classification [5].)

At the UN General Assembly in September 2024, countries agreed that by 2030 at least 70% of antibiotics used in human health globally should come from the Access group [6]. The companion WHO AWaRe Antibiotic Book gives empirical treatment guidance for more than 30 common infections in children and adults, in primary care and hospital, and is being updated to reflect newer guidelines [7].

Hospital stewardship programmes

The German S3 guideline on rational antibiotic use in hospitals (AWMF 092-001) was led by the German Society for Infectious Diseases, with Austrian societies among the partners, and was last updated in 2018. The English version of the first edition is open access [8]. It describes a stewardship team that includes at least an infectious diseases physician (or a clinician with ID training), an experienced clinical or hospital pharmacist and microbiology expertise, working with local treatment guidelines and surveillance of resistance and consumption [8]. In the UK, the "Start Smart then Focus" toolkit sets out comparable principles for inpatient care [9].

For resistance data, ECDC publishes European data from EARS-Net (resistance) and ESAC-Net (consumption) [1]. In Germany, the Robert Koch Institute's AMR portal provides the ARS resistance and AVS consumption databases [10]. For day-to-day decisions, your own hospital's antibiogram is still the most relevant source.

Seven principles for the ward

1. Send samples before the first dose

For sepsis or septic shock, the 2025 German S3 sepsis guideline recommends taking at least two sets of blood cultures before starting antibiotics, including in patients already on antibiotics, plus samples from the suspected source. Sampling must not substantially delay treatment [11]. "Start Smart then Focus" makes the same point: take cultures before starting therapy where possible, but do not delay treatment in severe sepsis [9].

2. Match urgency to the clinical picture

In sepsis, antimicrobials should be given as soon as possible, and in septic shock ideally within one hour. When sepsis is possible but there is no shock, the guideline suggests a rapid further work-up first. If infection is still suspected, antimicrobials should follow within three hours [11]. This helps avoid two opposite errors: delay in shock, and reflex broad-spectrum treatment for every unexplained fever.

3. Document the indication and the plan

"Start smart" means recording the working diagnosis, severity, drug, dose and route, plus the intended duration or a review date [9]. An antibiotic with no documented indication is very hard to review three days later, especially for the colleague covering the next shift.

4. Review at 48–72 hours

The German stewardship guideline recommends early de-escalation, after 48–72 hours. That means moving from empirical combination therapy to targeted monotherapy, and stopping treatment if the diagnosis is not confirmed. Observational studies found this was not done in 20–60% of cases [8]. The UK toolkit summarises the review options as "CARES": Cease, Amend (ideally to a narrower agent), Refer to outpatient services such as OPAT, Extend with a documented next review or stop date, or Switch from IV to oral [9]. Sometimes the right answer is to escalate. A review does not always mean doing less.

5. Switch to oral early

The German guideline recommends switching from parenteral to oral therapy when adequate bioavailability is assured and the patient's condition allows it (grade A). The switch should be assessed on day 3–4 of IV therapy [8]. Switching shortens hospital stay and reduces line-related complications. For moderate community-acquired pneumonia, the German S3 guideline explicitly recommends oral step-down once the patient improves [12].

6. As short as possible, as long as necessary

Many "standard" durations are historical. Where trials exist, shorter courses are often just as effective. Examples from German S3 guidelines:

The sepsis guideline also recommends procalcitonin measurement to help limit treatment duration once adequate source control has been achieved. Infections that need longer treatment anyway are excluded, such as S. aureus bacteraemia, endocarditis and candidaemia [11]. ECDC also singles out prolonged antibiotic use after surgery as a target for reduction [2].

7. Question penicillin allergy labels

Between 8% and 25% of people in most populations carry a penicillin allergy label. Most of these labels date from childhood and describe reactions that were not allergic, carry low risk, or reflect an allergy that has since waned [13]. The label has consequences: it leads to broader-spectrum, often less effective alternatives and is associated with antimicrobial resistance and adverse outcomes [13, 14]. A German quality-improvement project found that, with a structured algorithm, almost all patients with a reported penicillin allergy could receive cefuroxime as surgical prophylaxis, with no allergic reactions observed. Only patients with severe T-cell-mediated reactions were to avoid beta-lactams [15].

In practice, take a precise history (what happened, when, how severe) and document it. If the history is unclear or low-risk, arrange formal allergy assessment rather than carrying the label forward unchecked.

Common pitfalls

• Treating asymptomatic bacteriuria or colonisation because a culture came back positive.
• Going broad "just in case" and never de-escalating once cultures return.
• No stop date, so treatment continues because nobody makes an active decision.
• IV out of habit in a patient who is eating, drinking and stable.
• Empty allergy labels, such as "penicillin?" on the chart with no description of the reaction.

Summary

Stewardship starts with the first prescription, not with the ID consult. Send samples first, match urgency to the clinical picture, document indication and duration, review at 48–72 hours, switch to oral early, keep courses short and question allergy labels. Europe's targets of lower consumption and a higher Access share are met or missed on the ward. Your local guideline and stewardship team remain the reference for drug choice.

If you want to check what a guideline says on a specific point, you can ask Medelix. Its answers cite their sources so you can verify them in the original.

Sources

1. ECDC. Reducing antimicrobial resistance: is the EU progressing towards the 2030 targets? Press release, November 2023. ecdc.europa.eu
2. ECDC. European Antibiotic Awareness Day 2024: Key messages. antibiotic.ecdc.europa.eu
3. Council of the European Union. Council Recommendation of 13 June 2023 on stepping up EU actions to combat antimicrobial resistance in a One Health approach (2023/C 220/01). eur-lex.europa.eu
4. WHO. AWaRe classification of antibiotics for evaluation and monitoring of use, 2023. who.int
5. UK Health Security Agency. UK Access, Watch, Reserve, and Other classification for antibiotics (UK-AWaRe). gov.uk
6. WHO. World leaders commit to decisive action on antimicrobial resistance. 26 September 2024. who.int
7. WHO. The WHO AWaRe (Access, Watch, Reserve) antibiotic book. 2022. who.int
8. de With K, Allerberger F, Amann S, et al. Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection. 2016;44:395–439. doi:10.1007/s15010-016-0885-z
9. UK Health Security Agency. Start smart then focus: antimicrobial stewardship toolkit for inpatient care settings. gov.uk
10. Robert Koch Institute. AMR portal: ARS, AVS, ARVIA (German). amr.rki.de
11. German Sepsis Society et al. S3 guideline Sepsis – prevention, diagnosis, therapy and aftercare, 2025 update, short version (German). AWMF register no. 079-001. register.awmf.org
12. DGP, PEG, DGI et al. S3 guideline on the treatment of adults with community-acquired pneumonia – 2021 update (German). AWMF register no. 020-020. register.awmf.org
13. Stone CA, Trubiano J, Coleman DT, et al. The challenge of de-labeling penicillin allergy. Allergy. 2020;75(2):273–288. doi:10.1111/all.13848
14. Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183–198. doi:10.1016/S0140-6736(18)32218-9
15. Rüggeberg A, Lommel K, Tiedt N, Nickel E. Single-shot perioperative antibiotic prophylaxis in patients with a history of penicillin allergy: an algorithm for the safe administration of cefuroxime. Dtsch Arztebl Int. 2025;122(19):517–522. doi:10.3238/arztebl.m2025.0107